Cargando…

Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline

BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)‐4/IL‐13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add‐on dupilumab 200/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodila...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourdin, Arnaud, Papi, Alberto A., Corren, Jonathan, Virchow, J. Christian, Rice, Megan S., Deniz, Yamo, Djandji, Michel, Rowe, Paul, Pavord, Ian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820970/
https://www.ncbi.nlm.nih.gov/pubmed/33010038
http://dx.doi.org/10.1111/all.14611
_version_ 1783639322830831616
author Bourdin, Arnaud
Papi, Alberto A.
Corren, Jonathan
Virchow, J. Christian
Rice, Megan S.
Deniz, Yamo
Djandji, Michel
Rowe, Paul
Pavord, Ian D.
author_facet Bourdin, Arnaud
Papi, Alberto A.
Corren, Jonathan
Virchow, J. Christian
Rice, Megan S.
Deniz, Yamo
Djandji, Michel
Rowe, Paul
Pavord, Ian D.
author_sort Bourdin, Arnaud
collection PubMed
description BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)‐4/IL‐13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add‐on dupilumab 200/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodilator (pre‐BD) forced expiratory volume in 1 second (FEV(1)) and quality of life measures, and it was generally well tolerated in patients with uncontrolled, persistent (phase 2b), or moderate‐to‐severe (phase 3) asthma. METHODS: In patients on high‐dose inhaled corticosteroids (ICS) with type 2‐high asthma (subgroups including baseline blood eosinophils ≥150/300 cells/µL and/or fractional exhaled nitric oxide [FeNO] ≥25 ppb), annualized severe exacerbation rates over the treatment period, changes from baseline in pre‐BD FEV(1) and asthma control (5‐item asthma control questionnaire [ACQ‐5]) were analyzed. RESULTS: In high‐dose ICS type 2‐high subgroups, dupilumab 200/300 mg q2w vs placebo in the phase 2b (24 weeks) and phase 3 (52 weeks) studies significantly reduced severe exacerbations by 55%‐69%/57%‐60% (all P<.05) and 53%‐69%/48%‐66% (all P < .001), respectively, except in patients with ≥ 300 eosinophils/µL in phase 2b study (24%/50% (P = .52/0.15). Across subgroups, pre‐BD FEV(1) improved by 0.18‐0.22 L/0.19‐0.24 L (all P < .05) and 0.23‐0.36 L/0.15‐0.25 L (all P < .01) and ACQ‐5 scores were reduced by 0.46‐0.55/0.47‐0.85 (all P < .05) and 0.38‐0.50/0.24‐0.30 (all P < .05), respectively, except dupilumab 200 mg q2w in phase 2b in patients with FeNO ≥ 25 ppb (0.41; P = .09). Dupilumab was also effective in patients taking medium‐dose ICS. CONCLUSION: Dupilumab significantly reduced severe exacerbations and improved lung function and asthma control in patients with type 2‐high asthma on high‐dose ICS at baseline.
format Online
Article
Text
id pubmed-7820970
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78209702021-01-26 Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline Bourdin, Arnaud Papi, Alberto A. Corren, Jonathan Virchow, J. Christian Rice, Megan S. Deniz, Yamo Djandji, Michel Rowe, Paul Pavord, Ian D. Allergy ORIGINAL ARTICLES BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)‐4/IL‐13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add‐on dupilumab 200/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodilator (pre‐BD) forced expiratory volume in 1 second (FEV(1)) and quality of life measures, and it was generally well tolerated in patients with uncontrolled, persistent (phase 2b), or moderate‐to‐severe (phase 3) asthma. METHODS: In patients on high‐dose inhaled corticosteroids (ICS) with type 2‐high asthma (subgroups including baseline blood eosinophils ≥150/300 cells/µL and/or fractional exhaled nitric oxide [FeNO] ≥25 ppb), annualized severe exacerbation rates over the treatment period, changes from baseline in pre‐BD FEV(1) and asthma control (5‐item asthma control questionnaire [ACQ‐5]) were analyzed. RESULTS: In high‐dose ICS type 2‐high subgroups, dupilumab 200/300 mg q2w vs placebo in the phase 2b (24 weeks) and phase 3 (52 weeks) studies significantly reduced severe exacerbations by 55%‐69%/57%‐60% (all P<.05) and 53%‐69%/48%‐66% (all P < .001), respectively, except in patients with ≥ 300 eosinophils/µL in phase 2b study (24%/50% (P = .52/0.15). Across subgroups, pre‐BD FEV(1) improved by 0.18‐0.22 L/0.19‐0.24 L (all P < .05) and 0.23‐0.36 L/0.15‐0.25 L (all P < .01) and ACQ‐5 scores were reduced by 0.46‐0.55/0.47‐0.85 (all P < .05) and 0.38‐0.50/0.24‐0.30 (all P < .05), respectively, except dupilumab 200 mg q2w in phase 2b in patients with FeNO ≥ 25 ppb (0.41; P = .09). Dupilumab was also effective in patients taking medium‐dose ICS. CONCLUSION: Dupilumab significantly reduced severe exacerbations and improved lung function and asthma control in patients with type 2‐high asthma on high‐dose ICS at baseline. John Wiley and Sons Inc. 2020-10-21 2021-01 /pmc/articles/PMC7820970/ /pubmed/33010038 http://dx.doi.org/10.1111/all.14611 Text en © 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle ORIGINAL ARTICLES
Bourdin, Arnaud
Papi, Alberto A.
Corren, Jonathan
Virchow, J. Christian
Rice, Megan S.
Deniz, Yamo
Djandji, Michel
Rowe, Paul
Pavord, Ian D.
Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
title Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
title_full Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
title_fullStr Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
title_full_unstemmed Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
title_short Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
title_sort dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820970/
https://www.ncbi.nlm.nih.gov/pubmed/33010038
http://dx.doi.org/10.1111/all.14611
work_keys_str_mv AT bourdinarnaud dupilumabiseffectiveintype2highasthmapatientsreceivinghighdoseinhaledcorticosteroidsatbaseline
AT papialbertoa dupilumabiseffectiveintype2highasthmapatientsreceivinghighdoseinhaledcorticosteroidsatbaseline
AT correnjonathan dupilumabiseffectiveintype2highasthmapatientsreceivinghighdoseinhaledcorticosteroidsatbaseline
AT virchowjchristian dupilumabiseffectiveintype2highasthmapatientsreceivinghighdoseinhaledcorticosteroidsatbaseline
AT ricemegans dupilumabiseffectiveintype2highasthmapatientsreceivinghighdoseinhaledcorticosteroidsatbaseline
AT denizyamo dupilumabiseffectiveintype2highasthmapatientsreceivinghighdoseinhaledcorticosteroidsatbaseline
AT djandjimichel dupilumabiseffectiveintype2highasthmapatientsreceivinghighdoseinhaledcorticosteroidsatbaseline
AT rowepaul dupilumabiseffectiveintype2highasthmapatientsreceivinghighdoseinhaledcorticosteroidsatbaseline
AT pavordiand dupilumabiseffectiveintype2highasthmapatientsreceivinghighdoseinhaledcorticosteroidsatbaseline